Contact: Salimetrics (USA)
EVIDENCE-BASED SLEEP SCIENCE
Scientific References
Peer-reviewed research supporting the clinical value of Dim Light Melatonin Onset (DLMO) testing for circadian health assessment and sleep disorder treatment.
✓ 18 peer-reviewed publications
DLMO patterns have been shown to reliably predict circadian timing and help clinicians more accurately assess sleep behavior and phase shifts. Determining DLMO is also relevant in discriminating circadian rhythm-related sleep issues from other non-circadian disorders, and in establishing optimal timing for exogenous melatonin administration. The publications below highlight the growing scientific evidence for DLMO-guided sleep care.
AT-HOME DLMO ASSESSMENT
Murray, J. M., Stone, J. E., Abbott, S. M., et al. & International Association of Circadian Health Clinics (2024). A Protocol to Determine Circadian Phase by At-Home Salivary Dim Light Melatonin Onset Assessment. Journal of Pineal Research, 76(5), e12994.
An international 24-institution collaboration that reviewed at-home salivary DLMO literature and established a standardized clinical protocol. Recommendations cover lighting control, sampling rate, timing windows, and compliance monitoring — plus an optimization algorithm for minimizing sample count in DSWPD patients.
Key takeaway At-home DLMO is a validated, lower-cost circadian phase marker. Standardized protocol criteria enable its adoption as a routine diagnostic, monitoring, and treatment tool.
Burgess, H.J., Park, M., Wyatt, J.K., & Fogg, L.F. (2016). Home dim light melatonin onsets with measures of compliance in delayed sleep phase disorder. J. Sleep Res., 25(3), 314–317.
Tested a novel at-home saliva kit with objective light and timing monitors in 32 DSPD patients, comparing home vs. lab DLMO results across back-to-back assessments. Addressed the known risk that home DLMOs can be compromised by uncontrolled ambient light and sampling errors.
Key takeaway With built-in compliance measures, clinical-grade DLMO values are reliably obtainable by DSPD patients at home — removing a major barrier to circadian assessment.
Burgess, H.J., Wyatt, J.K., Park, M., & Fogg, L.F. (2015). Home Circadian Phase Assessments with Measures of Compliance Yield Accurate Dim Light Melatonin Onsets. Sleep, 38(6), 889–897.
Foundational study establishing that gold-standard DLMO measurement does not require a lab. A compliance-monitored home kit in healthy adults matched lab results, providing the scientific basis for at-home clinical DLMO assessment.
Key takeaway Home DLMO assessments with objective compliance measures are as accurate as lab-based assessments in healthy adults, opening the door for broad clinical deployment.
CLINICAL PRACTICE GUIDELINES
Auger, R. R., Burgess, H. J., Emens, J. S., et al. (2015) Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders (ASWPD, DSWPD, N24SWD, ISWRD). J. Clin. Sleep Med., 11(10), 1199–1236.
The official American Academy of Sleep Medicine evidence-based guideline for four major intrinsic circadian rhythm sleep-wake disorders. Covers recommended assessment tools including DLMO, and provides evidence-graded treatment recommendations (light therapy, melatonin) for each disorder subtype.
Key takeaway DLMO testing is formally endorsed in AASM guidelines as a key diagnostic tool across all major circadian sleep-wake disorder subtypes.
Keijzer H, Smits MG, Duffy JF, Curfs LM (2014). Why the dim light melatonin onset (DLMO) should be measured before treatment of patients with circadian rhythm sleep disorders.. Sleep Med. Rev., 18(4), 333–339.
Makes a direct clinical case for measuring DLMO before initiating treatment. Treatment timing for melatonin and light therapy depends critically on knowing the patient's actual circadian phase — administering therapy at the wrong phase can paradoxically worsen symptoms or shift the clock in the wrong direction.
Key takeaway Without pre-treatment DLMO measurement, clinicians risk administering therapy at suboptimal or counterproductive times. Measuring first is essential for safe, effective circadian disorder management.
DLMO AS A DIAGNOSTIC & RESEARCH TOOL
Pandi-Perumal, S. R., Smits, M., Spence, W., et al. (2007). Dim light melatonin onset (DLMO): a tool for the analysis of circadian phase in human sleep and chronobiological disorders.. Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 31(1), 1–11.
A comprehensive review establishing DLMO as the primary clinical and research tool for measuring circadian phase. Covers the biological basis of melatonin secretion, saliva vs. plasma methodology, and its application to diagnosing and timing treatment across sleep and chronobiological disorders.
Key takeaway DLMO is the most reliable, practical measure of the endogenous circadian clock in humans — useful for diagnosis, research endpoints, and timing light and melatonin therapies.
Lewy, A.J., Sack, R.L., Blood, M.L., et al. (1995). Melatonin marks circadian phase position and resets the endogenous circadian pacemaker in humans. Ciba Found. Symp., 183, 303–321.
Seminal work demonstrating that endogenous melatonin reliably marks the circadian clock position and that exogenous melatonin can shift (reset) the internal pacemaker. Established the foundational principle that melatonin timing relative to the internal clock determines whether it advances or delays circadian phase.
Key takeaway Melatonin is both a marker of circadian phase and an active clock-resetting agent. This dual role forms the scientific basis for using DLMO to guide precise melatonin therapy timing.
Molina, T.A., & Burgess, H.J. (2011). Calculating the dim light melatonin onset: the impact of threshold and sampling rate. Chronobiol. Int., 28(8), 714–718.
A methodological study examining how threshold choice and sampling frequency (30 vs. 60 min intervals) affect the calculated DLMO time, giving practical guidance for selecting protocols. Compared results across different threshold methods and intervals.
Key takeaway The difference in DLMO estimation between half-hourly and hourly sampling is generally not significant, supporting practical hourly at-home collection. Consistent threshold methodology is critical for comparable results.
CIRCADIAN MISALIGNMENT & HEALTH OUTCOMES
Murray, J.M., Sletten, T.L., Magee, M., et al. (2017). Prevalence of Circadian Misalignment and Its Association With Depressive Symptoms in Delayed Sleep Phase Disorder. Sleep, 40(1).
Used salivary DLMO in 182 DSPD patients to determine which had a true circadian basis for their disorder vs. a behavioral or non-circadian cause. Found that nearly half (43%) of clinically diagnosed DSPD patients lacked objective circadian misalignment — underscoring why DLMO measurement is essential for accurate diagnosis.
Key takeaway Circadian DSPD patients had their DLMO 1.66 hrs later than non-circadian cases and were over 4× more likely to experience significant depressive symptoms, linking true circadian misalignment directly to mental health risk.
Fishbein, A. B., Knutson, K. L., & Zee, P. C. (2021). Circadian disruption and human health. J. Clin. Invest., 131(19), e148286.
A major bench-to-bedside review from Northwestern examining circadian disruption's consequences across neurologic, psychiatric, metabolic, cardiovascular, allergic, and immunologic disorders. Argues the relationship is bidirectional — disruption worsens disease, and disease disrupts circadian rhythms — and highlights circadian-based interventions as personalized medicine opportunities.
Key takeaway Circadian disruption increases risk and severity of a wide spectrum of diseases. Properly timed light and melatonin therapies represent a broadly applicable, precision medicine approach to improving outcomes.
Zelinski, E.L., Deibel, S.H., & McDonald, R.J. (2014). The trouble with circadian clock dysfunction: multiple deleterious effects on the brain and body. Neurosci. Biobehav. Rev., 40, 80–101.
A sweeping review of animal and human evidence showing that circadian clock dysfunction impairs cognition, learning, mood, metabolism, immune function, and cancer risk. Makes the case that healthy circadian timing is fundamental to brain and bodily health well beyond sleep.
Key takeaway Circadian dysfunction cascades into cognitive impairment, metabolic dysregulation, immune disruption, and elevated cancer risk — underscoring the importance of circadian monitoring and intervention.
MELATONIN BIOLOGY & PHYSIOLOGY
Cipolla-Neto, J., & Gaspar do Amaral, F. (2018) Melatonin as a Hormone: New Physiological and Clinical Insights. Endocrine Reviews, 39(6), 990–1028.
Repositions melatonin beyond its classical sleep role to a broader endocrine regulator governing energy metabolism, reproductive function, immune modulation, antioxidant defense, and cardiovascular health. Reviews the clinical consequences of melatonin suppression by nighttime light exposure.
Key takeaway Melatonin functions as a broad physiological hormone. Its suppression by evening light or misaligned schedules affects metabolic, immune, and cardiovascular health — not just sleep timing.
Arendt, J. & Aulinas, A. (2022). Physiology of the Pineal Gland and Melatonin. In: Feingold KR et al. (eds.), Endotext [Internet]. MDText.com, Inc. PMID: 31841296.
A comprehensive reference chapter covering the full physiology and pathophysiology of the pineal gland and melatonin, authored by two leading figures in circadian biology. Topics include the neural pathway from light detection to melatonin synthesis, the role of melatonin as a darkness-driven circadian signal, its metabolism and lifespan trajectory, receptor mechanisms, and its clinical application across delayed sleep phase syndrome, jet lag, non-24-hour sleep-wake disorder, and neurodegenerative conditions. The chapter also reviews factors that suppress or alter melatonin secretion, including light, medications, aging, and disease.
Key takeaway
Melatonin is the primary hormonal output of the circadian clock, secreted exclusively during darkness and suppressed by light. Its timing — not just its presence — determines its clinical effect. DLMO assessment is explicitly identified as a valid, reliable indicator of circadian phase position and the appropriate guide for timing melatonin therapy in individual patients.
Dollish, H.K., Tsyglakovam, M., McClung, C.A. (2024). Circadian rhythms and mood disorders: Time to see the light.. Journal.
A recent authoritative review of mechanistic links between the circadian system and mood disorders, including depression and bipolar disorder. Covers genetics, neural circuits, and human clinical evidence, highlighting light as a key modulator of both circadian timing and mood-relevant neural pathways.
Key takeaway Circadian disruption and mood disorders share deep mechanistic roots. Light exposure timing — which drives DLMO — is a central lever for both circadian and mental health, with direct implications for chronotherapy and light treatment.
SALIVARY MEASUREMENT VALIDATION
Nagtegaal, E., Peeters, T., Swart, W., et al. (1998). Correlation between concentrations of melatonin in saliva and serum in patients with delayed sleep phase syndrome. Ther. Drug Monit., 20(2), 181–183.
Early validation comparing simultaneous salivary and serum melatonin concentrations in DSPD patients, showing saliva accurately reflects blood levels. Provided the clinical foundation for using non-invasive saliva collection in place of serial blood draws for DLMO testing.
Key takeaway Salivary melatonin correlates closely with serum concentrations in DSPD patients, validating saliva as a practical, non-invasive substitute for blood-based DLMO assessment.
Voultsios, A., Kennaway, D.J., & Dawson, D. (1997). Salivary melatonin as a circadian phase marker: validation and comparison to plasma melatonin. . J. Biol. Rhythms, 12(5), 457–466.
Formal validation comparing simultaneous saliva and plasma melatonin samples across evening and night. Demonstrated that salivary melatonin accurately tracks plasma timing and amplitude with acceptable reliability, cementing the scientific credibility of saliva-based DLMO determination.
Key takeaway Salivary melatonin is a validated circadian phase marker that closely parallels plasma, confirming that salivary DLMO can replace invasive plasma-based measurement in most clinical applications.
DLMO, SLEEP TIMING & INSOMNIA
Wright, H., Lack, L. & Bootzin, R. (2006). Relationship between dim light melatonin onset and the timing of sleep in sleep onset insomniacs. Sleep Biol. Rhythms, 4, 78–80.
Investigated the relationship between DLMO timing and habitual sleep onset in sleep onset insomnia patients. Provided evidence that delayed circadian phase — detectable via DLMO — underlies sleep initiation difficulties in a meaningful subset of insomnia patients distinct from purely behavioral causes.
Key takeaway DLMO timing is significantly related to sleep onset in insomnia patients, suggesting that circadian phase assessment should inform treatment planning rather than defaulting exclusively to behavioral interventions.
LIGHT EXPOSURE RECOMMENDATIONS
Brown, T. M., Brainard, G. C., Cajochen, C., et al. (2022). Recommendations for daytime, evening, and nighttime indoor light exposure to best support physiology, sleep, and wakefulness in healthy adults. PLOS Biology, 20(3), e3001571.
Expert consensus providing evidence-based indoor light exposure recommendations across the 24-hour day: higher, bluer light during daytime for alertness and circadian entrainment; reduced, warmer light in the evening to protect natural melatonin onset; and minimal light at night to preserve sleep quality.
Key takeaway Strategic indoor light management — particularly evening light reduction — is critical to preserving natural DLMO timing and sleep quality. These recommendations directly complement DLMO-guided clinical care.
Ready to Assess Your Circadian Timing?
At-home salivary DLMO testing is now available. Convenient, validated, and clinician-guided.